Silicon Valley startup pursues AI-driven embryo gene editing despite global ban
Preventive, a startup backed by Sam Altman and Brian Armstrong, reportedly pursued AI-driven embryo gene editing to prevent hereditary diseases, circumventing U.S. bans by exploring jurisdictions like the UAE. The practice raises concerns about eugenics, unintended genetic consequences, and violates global scientific consensus on such research.
What happened
Preventive, a Silicon Valley startup founded in May 2025 and backed by OpenAI CEO Sam Altman and Coinbase founder Brian Armstrong, reportedly worked discreetly on genetically engineering human embryos to prevent hereditary diseases.
According to the Wall Street Journal, Preventive identified a couple with a genetic disease for the research and explored countries where embryo gene editing is permitted, including the United Arab Emirates. Preventive CEO Lucas Harrington denied claims that a couple had been identified for the research.
Reported impact
Gene editing of embryos to create designer babies raises ethical concerns about eugenics and unintended consequences. Experts warn that modifications to embryonic DNA could be transmitted to future generations and are scientifically unpredictable.
Index analysis
Embryo gene editing is banned in the United States and many other countries worldwide. The practice circumvents global scientific consensus on the need for a moratorium due to ethical and safety concerns.
Governance controls
No governance controls prevented the startup from pursuing the research or seeking jurisdictions where the practice is legal.
Classification
Sources and evidence
This record was researched and written by the Index, based on the following original reporting.